Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase 1/2 Study of Radium-223 Dichloride in Combination With Pembrolizumab in Participants With Stage IV Non-small Cell Lung Cancer

NCT03996473 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03996473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03996473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase 1/2 Study of Radium-223 Dichloride in Combination With Pembrolizumab in Participants With Stage IV Non-small Cell Lung Cancer
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Terminated
Start date
March 6, 2020
Completion date
January 30, 2023
Enrollment
8 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung